"Another project with the potential to address an area of unmet medical need is in the treatment of non-melanoma skin cancer (NMSC). We have put the R&D activities for these projects on hold as we determine the future of the relationship with Hexima. Hexima have stated that the NMSC collaboration has ended and has purported to terminate the Antifungal project Collaboration Agreement. We have not received any formal notice from Hexima regarding the status of the NMSC project despite Hexima advising shareholders at its recent AGM that the collaboration with Acrux has ended. Contrary to Hexima’s advice to shareholders, Acrux has not formally advised Hexima that it does not wish to continue the NMSC project and the NMSC Collaboration Agreement has not been terminated."
hang on - is the executive chairman for hexima not sitting nearby??? - well ask him now about that - let's all know where we stand on this now or are we to be let known when he leaves for whatever reason??.
anyhow reading all this presentation - very similar to last years - all set to go but someone forgot to pull the trigger on the starters gun!. all IMO and very much hope to be proven wrong.and then
like this bit - "Turning to Acrux, over the last 12 months the company has reviewed and revised its strategy. As part of that review, we have updated our internal company valuation model in order to understand the true value to the business of our major asset, Axiron as well as the other levers available to help us create value for shareholders. That has led, in part, to the changes in management announced recently. - thought this should have been attended to some time ago - oh well better late than never I guess and can only look forward on a positive note. Can only await to see if the promising words end up with the results we are all awaiting.
Add to My Watchlist
What is My Watchlist?
